Global Dyslipidemia Drugs Market to Grow at a CAGR of 5.27%, 2017-2021 With AstraZeneca, Merck, Pfizer & Sanofi Leading the Way - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Dyslipidemia Drugs Market 2017-2021" report to their offering.

The global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.

The report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one driver in the market is increasing risk of CVDs. Elevated levels of cholesterol in the blood lead to the deposition of cholesterol in the arterial walls, which results in atherosclerosis, hardening and narrowing the arteries. The resultant narrowing of blood vessels decreases the blood flow to the heart muscles, causing a heart attack. High cholesterol levels account for nearly one-third of all ischemic heart diseases and hence, remain a significant cause of ischemic heart diseases and strokes in developed and developing countries such as India and China. Data estimates suggest that among men aged 40 years and over, a 10% decrease in serum cholesterol levels reduces the risk of heart disease by 50% within five years.

Hence, cardiovascular risk management guidelines by authorities such as the American College of Cardiology and American Heart Association consider reducing blood cholesterol an important factor in reducing cardiovascular risk. As cholesterol disorder is one of the major causes for CVDs, patients try to strictly adhere to cholesterol maintaining drugs to avoid the occurrence of CVD. This preventive approach toward the occurrence of CVDs will further boost the sales of cholesterol controlling agents.

Key vendors

  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of dyslipidemia

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by drug class

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/v6dd2m/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs